Cision Portugal SA: Italian pharmaceutical company Alfasigma launches diagnostic drug Lumeblue ahead of World Digestive Health on 29 May

- WDHD 2022 is dedicated to raising awareness on colorectal cancer prevention - In Europe more than 519,820 new cases of colorectal cancer (CRC) were diagnosed in 2020 - Adenoma detection

Related Keywords

Italy ,Mexico ,Poland ,United Kingdom ,Russia ,Switzerland ,Warsaw ,L67 ,Italian ,Alessandro Repici ,Michal Kaminski ,Prateek Sharma ,Cosmo Pharmaceuticals ,Prnewswire Ahead Of World Digestive Health ,Head Of The Department Cancer Prevention ,Institute Of Oncology ,University Of Kansas School Medicine ,Maria Sklodowska Curie Memorial Cancer Center ,Kansas City Veterans Affairs Medical Centre ,Department Of Gastroenterological Oncology ,European Medicines Agency ,World Digestive Health ,Cancer Prevention ,Endoscopy Unit ,Gastroenterological Oncology ,Colon Rectal Cancer ,Section Chief ,Program Director ,Kansas School ,Humanitas University Medical School ,European Economic Area ,Decision ,Portugal ,Harmaceutical ,Company ,Alfasigma ,Aunches ,Iagnostic ,Drug ,Umeblue ,Head ,World ,Digestive ,Health ,